Retinol Binding Protein, Random, Urine
Iron, Serum
Dopamine beta-hydroxylase (DBH) Genetic Variations
Flunitrazepam, Urine
Hepatitis E Virus (HEV) Antibody, IgM
Hematolymphoid Neoplasm Gene Mutation Panel, NGS
Tuberculosis Cell Mediated Immunity Antigen Response (T-SPOT®. TB) Test
Cytomegalovirus (CMV) Antibody, IgG, IgM
Methanol
Protein C, Total Antigen
LDS
Sign up
Log in
LDS
/
Medical Tests
/
ABL1 Kinase Domain Mutation Analysis for Tyrosine Kinase Inhibitor Resistance in CML, NGS
All
Diseases
Overview
Clinical Utility
Interpretation
Reference Ranges
Methodology
Specimen Collection
Additional Testing
Turnaround Time
CPT
LOINC
ICD10
Additional ICD10
References
All
Diseases
Overview
Clinical Utility
Interpretation
Reference Ranges
Methodology
Specimen Collection
Additional Testing
Turnaround Time
CPT
LOINC
ICD10
Additional ICD10
References
ABL1 Kinase Domain Mutation Analysis for Tyrosine Kinase Inhibitor Resistance in CML, NGS
Medical Test
Interpretation
Access to
ABL1 Kinase Domain Mutation Analysis for Tyrosine Kinase Inhibitor Resistance in CML, NGS
is restricted.
Sign up now
Loading...